GlaxoSmithKline says Tykerb doubles time to progression for breast cancer patients

By Elaine Rigoli

Tampa, Fla., June 5 - GlaxoSmithKline plc said Monday that the results from a large, randomized phase 3 study of Tykerb and capecitabine (Xeloda) versus capecitabine alone nearly doubled time to progression (36.9 weeks in the combination arm versus 19.7 weeks with capecitabine alone) in women with refractory advanced or metastatic ErbB2 positive breast cancer whose disease had progressed following treatment with trastuzumab (Herceptin) and other cancer therapies.

Tykerb is an investigational drug and is not yet approved for marketing by any regulatory body.

GlaxoSmithKline said it plans to file for regulatory approval of Tykerb in the United States and Europe in the second half of 2006.

GlaxoSmithKline, based in London, is a global research-based pharmaceutical and health care company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.